Sareum Share News (SAR)

Sareum Information

Buy SAR Shares
Add SAR to Watchlist
Add SAR to Alert

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 24.25

Bid: 24.00

Ask: 24.50

Change: 0.00 (0.00%)

Spread: 0.50 (2.083%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 24.25

Last checked at -

Sareum Holdings selects cancer therapy development candidate

Wed, 26th Sep 2018 15:20

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.The AIM-traded firm said the candidate molecule, SDC-1802, demonstrated "high selectivity" for TYK2 and JAK1 kinases - particularly over related JAK2 and JAK3.It said SDC-1802 showed "compelling" efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile.In addition, Sareum said it had generated "encouraging evidence" to suggest that those molecules could function as cancer immunotherapy by modulating the host's immune system to block tumour cell proliferation in disease models of certain kidney, colon, skin and pancreatic cancers.Sareum said it intended to progress SDC-1802 into preclinical development and, pending satisfactory progress, into human clinical trials which could begin in 2020.The company owned the commercialisation rights for the candidates and other dual TYK2/JAK1 inhibitors with profiles optimised for oncology indications.It had announced on 10 September that it was also advancing SDC-1801 as a distinct dual TYK2/JAK1 inhibitor for the potential treatment of autoimmune diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel disease and lupus.SDC-1802 also had the potential to act as a backup molecule for these autoimmune indications."We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases," said chief executive officer Dr Tim Mitchell."The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications."Dr Mitchell said both candidates had produced exciting results in preclinical disease models, and believed present valuable opportunities for licensing and further development."Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020."

More News

7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December
Amedeo Air Four Plus Ltd	AGM
Ashoka India Equity Investment Trust PLC	AGM
Associated British Engineering PLC	AGM
Associated British Foods PLC	AGM
Corcel PLC	GM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLC	AGM
URA Holdings PLC	GM re closing the fundraise
Monday 11 December
IamFire PLC	AGM with vote on name change to WeCap PLC
Pharma C Investments PLC	GM re allowing investments in fintech, AI sectors
SigmaRoc PLC	GM re reverse takeover
Tribal Group PLC	GM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLC	AGM
Tuesday 12 December
Atalaya Mining PLC	EGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLC	AGM
Distil PLC	GM re placing and subscription
Gelion PLC	AGM
Wednesday 13 December
Dechra Pharmaceuticals PLC	AGM
Limitless Earth PLC	AGM
Softcat PLC	AGM
Volution Group PLC	AGM
Thursday 14 December
Aeorema Communications PLC	AGM
CleanTech Lithium PLC	GM re equity raise approval
Driver Group PLC	Full Year Results
eEnergy Group PLC	AGM
Ethernity Networks Ltd	GM re authority to allot shares on non-preemptive basis
Fintech Asia Ltd	AGM
Helium One Global Ltd	AGM
Marwyn Value Investors Ltd	AGM
Quarto Group Inc	GM re cancelling trading on London's Main Market
Sareum Holdings PLC	AGM

Copyright 2023 Alliance News Ltd. All Rights Reserved.

23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

3 Nov 2023 13:59

Sareum secures Japan patent for kinase inhibitor asset

(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.

3 Nov 2023 09:01

Sareum says patent notice in Japan boosts confidence in SDC-1801

(Alliance News) - Sareum Holdings PLC on Friday said it received a notice of allowance from Japan's Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.

9 Oct 2023 15:06

Sareum losses widen as clinical trials continue

(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.

9 Oct 2023 10:58

Sareum says earnings down but product development going well

(Alliance News) - Sareum Holdings PLC on Monday said its annual loss widened and its cash reserves are substantially reduced, but that development and testing of its medicinal products is progressing well.

6 Sep 2023 14:35

Director dealings: Blackbird, Sareum insiders pick up shares

(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.

4 Sep 2023 09:18

Sareum begins dosing participants in phase 1a trial for SDC-1801

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee.

16 Aug 2023 13:13

Sareum flagship drug trial progressing well ahead of annual results

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development.

3 Aug 2023 14:16

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs.

26 Jun 2023 17:33

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News:

26 Jun 2023 10:54

Sareum granted new patents in China, US

(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.

6 Jun 2023 13:36

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Latest Share Chat

Sareum Share News (SAR)

Share Price Information for Sareum (SAR)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum Holdings selects cancer therapy development candidate

Login to your account

Quickpicks are a member only feature

Login to your account